vs
安捷伦科技（A）与SELECT MEDICAL HOLDINGS CORP（SEM）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是SELECT MEDICAL HOLDINGS CORP的1.3倍（$1.8B vs $1.4B）。安捷伦科技净利率更高（17.0% vs 1.4%，领先15.5%）。安捷伦科技同比增速更快（7.0% vs 6.4%）。安捷伦科技自由现金流更多（$175.0M vs $5.2M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs 2.8%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Select Medical是总部位于美国宾夕法尼亚州的医疗健康企业，业务涵盖长期急症护理、住院康复医院运营，同时开设有职业健康与物理治疗诊所，母公司Select Medical Holdings在纽约证券交易所挂牌上市。
A vs SEM — 直观对比
营收规模更大
A
是对方的1.3倍
$1.4B
营收增速更快
A
高出0.6%
6.4%
净利率更高
A
高出15.5%
1.4%
自由现金流更多
A
多$169.8M
$5.2M
两年增速更快
A
近两年复合增速
2.8%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.4B |
| 净利润 | $305.0M | $20.2M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 4.6% |
| 净利率 | 17.0% | 1.4% |
| 营收同比 | 7.0% | 6.4% |
| 净利润同比 | -4.1% | 225.7% |
| 每股收益（稀释后） | $1.07 | $0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASEM
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.4B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.3B |
净利润ASEM
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $20.2M | ||
| Q3 25 | $336.0M | $28.8M | ||
| Q2 25 | $215.0M | $40.6M | ||
| Q1 25 | $318.0M | $56.7M | ||
| Q4 24 | $351.0M | $-16.1M | ||
| Q3 24 | $282.0M | $55.6M | ||
| Q2 24 | $308.0M | $77.6M |
毛利率ASEM
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率ASEM
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 4.6% | ||
| Q3 25 | 20.7% | 5.4% | ||
| Q2 25 | 18.0% | 6.5% | ||
| Q1 25 | 22.4% | 8.3% | ||
| Q4 24 | 24.0% | 1.6% | ||
| Q3 24 | 21.1% | 4.3% | ||
| Q2 24 | 23.1% | 5.8% |
净利率ASEM
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 1.4% | ||
| Q3 25 | 19.3% | 2.1% | ||
| Q2 25 | 12.9% | 3.0% | ||
| Q1 25 | 18.9% | 4.2% | ||
| Q4 24 | 20.6% | -1.2% | ||
| Q3 24 | 17.9% | 4.4% | ||
| Q2 24 | 19.6% | 6.1% |
每股收益（稀释后）ASEM
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.17 | ||
| Q3 25 | $1.18 | $0.23 | ||
| Q2 25 | $0.75 | $0.32 | ||
| Q1 25 | $1.11 | $0.44 | ||
| Q4 24 | $1.23 | $-0.12 | ||
| Q3 24 | $0.97 | $0.43 | ||
| Q2 24 | $1.05 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $26.5M |
| 总债务越低越好 | $3.0B | $1.8B |
| 股东权益账面价值 | $6.9B | $1.7B |
| 总资产 | $12.8B | $5.9B |
| 负债/权益比越低杠杆越低 | 0.44× | 1.06× |
8季度趋势，按日历期对齐
现金及短期投资ASEM
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $26.5M | ||
| Q3 25 | $1.5B | $60.1M | ||
| Q2 25 | $1.5B | $52.3M | ||
| Q1 25 | $1.5B | $53.2M | ||
| Q4 24 | $1.3B | $59.7M | ||
| Q3 24 | $1.8B | $191.5M | ||
| Q2 24 | $1.7B | $111.2M |
总债务ASEM
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $1.8B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.3B | $1.8B | ||
| Q1 25 | $3.3B | $1.8B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.1B | $3.6B |
股东权益ASEM
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.7B | ||
| Q3 25 | $6.4B | $1.7B | ||
| Q2 25 | $6.1B | $1.7B | ||
| Q1 25 | $6.0B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $5.9B | $1.9B | ||
| Q2 24 | $6.2B | $1.4B |
总资产ASEM
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $5.9B | ||
| Q3 25 | $12.2B | $5.7B | ||
| Q2 25 | $12.2B | $5.7B | ||
| Q1 25 | $11.9B | $5.7B | ||
| Q4 24 | $11.8B | $5.6B | ||
| Q3 24 | $11.0B | $8.0B | ||
| Q2 24 | $10.9B | $7.9B |
负债/权益比ASEM
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.06× | ||
| Q3 25 | 0.53× | 1.03× | ||
| Q2 25 | 0.55× | 1.10× | ||
| Q1 25 | 0.56× | 1.03× | ||
| Q4 24 | 0.57× | 1.01× | ||
| Q3 24 | 0.36× | 1.62× | ||
| Q2 24 | 0.34× | 2.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $64.3M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $5.2M |
| 自由现金流率自由现金流/营收 | 9.7% | 0.4% |
| 资本支出强度资本支出/营收 | 5.2% | 4.2% |
| 现金转化率经营现金流/净利润 | 0.88× | 3.19× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $117.2M |
8季度趋势，按日历期对齐
经营现金流ASEM
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $64.3M | ||
| Q3 25 | $362.0M | $175.3M | ||
| Q2 25 | $221.0M | $110.3M | ||
| Q1 25 | $431.0M | $-3.5M | ||
| Q4 24 | $481.0M | $125.4M | ||
| Q3 24 | $452.0M | $181.0M | ||
| Q2 24 | $333.0M | $278.2M |
自由现金流ASEM
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $5.2M | ||
| Q3 25 | $259.0M | $122.2M | ||
| Q2 25 | $107.0M | $45.6M | ||
| Q1 25 | $334.0M | $-55.8M | ||
| Q4 24 | $388.0M | $62.0M | ||
| Q3 24 | $360.0M | $130.3M | ||
| Q2 24 | $230.0M | $222.6M |
自由现金流率ASEM
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 0.4% | ||
| Q3 25 | 14.9% | 9.0% | ||
| Q2 25 | 6.4% | 3.4% | ||
| Q1 25 | 19.9% | -4.1% | ||
| Q4 24 | 22.8% | 4.7% | ||
| Q3 24 | 22.8% | 10.2% | ||
| Q2 24 | 14.6% | 17.4% |
资本支出强度ASEM
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 4.2% | ||
| Q3 25 | 5.9% | 3.9% | ||
| Q2 25 | 6.8% | 4.8% | ||
| Q1 25 | 5.8% | 3.9% | ||
| Q4 24 | 5.5% | 4.8% | ||
| Q3 24 | 5.8% | 4.0% | ||
| Q2 24 | 6.5% | 4.3% |
现金转化率ASEM
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 3.19× | ||
| Q3 25 | 1.08× | 6.09× | ||
| Q2 25 | 1.03× | 2.72× | ||
| Q1 25 | 1.36× | -0.06× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | 3.25× | ||
| Q2 24 | 1.08× | 3.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
